Purple Biotech Asset Resilience Ratio
Purple Biotech asset resilience ratio. Purple Biotech (PPBT) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Purple Biotech (PPBT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Purple Biotech (2016–2025)
Asset resilience ratio of Purple Biotech from 2016 to 2025. This chart shows how Purple Biotech's Asset Resilience Ratio has changed over time. Read PPBT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Purple Biotech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Purple Biotech.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $869.00K | 6.13% |
| Total Liquid Assets | $869.00K | 6.13% |
Asset Resilience Insights
- Limited Liquidity: Purple Biotech maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Purple Biotech Industry Peers by Asset Resilience Ratio
Compare Purple Biotech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Purple Biotech Asset Resilience Ratio by Year (2016–2025)
Purple Biotech asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Purple Biotech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.88% | $856.99K | $17.57 Million | +1.85pp |
| 2024-12-31 | 3.03% | $1.12 Million | $37.04 Million | +0.95pp |
| 2023-12-31 | 2.08% | $923.00K | $44.30 Million | -29.19pp |
| 2022-12-31 | 31.27% | $17.08 Million | $54.62 Million | -20.45pp |
| 2021-12-31 | 51.73% | $36.31 Million | $70.20 Million | -3.83pp |
| 2020-12-31 | 55.56% | $46.56 Million | $83.80 Million | +41.90pp |
| 2019-12-31 | 13.66% | $2.01 Million | $14.72 Million | +3.33pp |
| 2018-12-31 | 10.33% | $1.52 Million | $14.72 Million | -14.26pp |
| 2017-12-31 | 24.59% | $3.49 Million | $14.18 Million | -28.37pp |
| 2016-12-31 | 52.96% | $7.90 Million | $14.91 Million | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more